Evofem Biosciences extends maturity of Adjuvant convertible notes by six months

Evofem Biosciences, Inc.

Fourth Amendment to Securities Purchase Agreement dated April 10, 2026 with Adjuvant Global Health Technology Fund.
Notes now due six months after April 10, 2026 (approx. Oct 10, 2026), or upon change of control or acceleration.
No prepayment of notes allowed before that six-month date without Adjuvant's prior written consent.
Amendment updates maturity definition in Section 3.1 of the Purchase Agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Evofem Biosciences, Inc. amended Fourth Amendment with Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. (together, Adjuvant) (effective 2026-04-10).

Action: amendment
Agreement: equity purchase
Counterparty: Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. (together, Adjuvant)
Effective: 2026-04-10

Exact text from the filing

On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).

View on SEC.gov

Browse all material agreements →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-017082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.